BioCardia (BCDA)
(Real Time Quote from BATS)
$2.82 USD
-0.09 (-3.09%)
Updated Jul 22, 2024 01:02 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BCDA 2.82 -0.09(-3.09%)
Will BCDA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCDA
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BCDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
Other News for BCDA
Biotech Alert: Searches spiking for these stocks today
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
BioCardia announces US Patent Office granted patent on Morph DNA
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
Biotech Alert: Searches spiking for these stocks today